1614-06-8

Upstream product

• 861361-81-1 2-(4-nitro-phenyl)-1⁽³⁾H-imidazole-4-carboxylic acid 
• 7664-93-9 sulfuric acid 
• 555-16-8 4-nitrobenzaldehdye 
• 107-15-3 ethylenediamine 
• 22483-09-6 2,2-dimethoxyethylamine 
• 619-72-7 4-nitrobenzonitrile 
• 288-32-4 1H-imidazole 
• 100-01-6 4-nitro-aniline 
• 122-04-3 4-nitro-benzoyl chloride 
• 7732-18-5 water 
• 98-95-3 nitrobenzene 
• 50846-98-5 2-Diazo-2H-imidazole 
• 670-96-2 2-Phenylimidazole 
• 61033-70-3 2-(4-nitrophenyl)-4,5-dihydro-1H-imidazoline 

Downstream Products

• 1160826-48-1 C₁₆H₁₀N₄O₅ 
• 1160826-55-0 C₁₆H₁₀BrN₃O₃ 
• 1220701-15-4 C₁₄H₁₁N₅O₂S 
• 245547-15-3 4-(1-methyl-1H-imidazol-2-yl)aniline 
• 1400866-39-8 C₂₀H₂₀N₄O₃ 
• 1400866-35-4 C₁₇H₁₄N₄O₃ 
• 1253697-42-5 2-(4-nitrophenyl)-1-(phenylsulfonyl)-1H-imidazole 
• 13682-33-2 4-(1H-imidazol-2-yl)-aniline 

Relevant academic research and scientific papers

Direct Oxidative Conversion of Benzoyl Chlorides to 2-Imidazoles Using Heteropolyacids

The reaction of benzoyl chlorides with ethylenediamine in the presence of catalytic amounts of Keggin-type heteropolyacids led to oxidative conversion of benzoyl chlorides to the corresponding 2-imidazoles in good yields.

Identification of Piperidine-3-carboxamide Derivatives Inducing Senescence-like Phenotype with Antimelanoma Activities

This study evaluated the potential use of senescence-inducing small molecules in the treatment of melanoma. We screened commercially available small-molecule libraries with high-throughput screening and high-content screening image-based technology. Our findings showed an initial hit with the embedded N-arylpiperidine-3-carboxamide scaffold-induced senescence-like phenotypic changes in human melanoma A375 cells without serious cytotoxicity against normal cells. A focused library containing diversely modified analogues were constructed and examined to evaluate the structure-activity relationship of N-arylpiperidine-3-carboxamide derivatives starting from hit 1. This work identified a novel compound with remarkable antiproliferative activity in vitro and demonstrated the key structural moieties within.

Highly efficient protocol for the aromatic compounds nitration catalyzed by magnetically recyclable core/shell nanocomposite

An efficient protocol for the nitration of aromatic compounds in the presence of a catalytic amount of sulfuric acid-functionalized silica-based magnetic core/shell nanocomposite was reported. The designed products were obtained in high yields in relatively short reaction times at room temperature under solvent-free conditions. The nanocatalyst was simply recovered from the reaction mixture by using an external magnet and efficiently reused for several times. The characterization of particle size, morphology and elemental analysis of the nanocatalyst were provided by scanning electron microscopy, transmission electron microscopy and energy-dispersive X-ray spectroscopy analyses, respectively.

HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions in need of inhibition of heparan sulfate biosynthesis.

Fe3O4/SiO2/(CH2)3N+Me3Br3- core-shell nanoparticles: A novel catalyst for the solvent-free synthesis of five- and six-membered heterocycles

Functionalized magnetic core-shell nanoparticles [Fe3O4/SiO2/(CH2)3N+Me3Br3-] are prepared by co-precipitation method, characterized by transmission electron microscopy, FT-IR, X-ray diffraction, and vibrating sample magnetometer. The catalytic activity of these nanoparticles was tested in the syntheses of imidazole, benzothiazole, and perimidine derivatives, under solvent-free conditions. The catalyst was readily recycled by the use of an external magnetic field and could be reused five times without significant loss of activity or mass.

Synthesis, antimicrobial activities and binding mode analysis of some novel N-substituted imidazoles and nitroimidazoles

Novel N-((2-(aryl)-imidazol-1-yl) methyl)-anilines 2a-n and 1-(3'-arylamino-2'- hydroxypropyl)-2-methyl-4-nitroimidazoles 4a-g have been synthesized. The compounds have been characterized on the basis of elemental analysis and spectral data. All the compounds were evaluated for their antibacterial activities. Among the synthesized compounds, compounds 2m, 2n and compounds 4c, 4e exhibited highest inhibitory activity against all the bacterial strains, comparable to the standard drug ciprofloxacin. Binding mode analysis of the highest active compounds was carried out in the active site of GlcN-6-P synthase (2VF5).

COMPOUNDS FOR TREATMENT OF CANCER

The present invention relates to pharmaceutical compositions for treating cancer comprising BRAF inhibitors, (e.g. vemurafenib) and/or MEK inhibitor, (e.g. trametinib, RO5068760), in combination with anti-tubulin compounds of the invention or other known tubulin inhibitors, and using such compositions for treating cancer such as melanoma, drug-resistant cancer, and cancer metastasis.

An efficient and convenient synthesis of imidazolines and benzimidazoles via oxidation of carbon-nitrogen bond in water media

The metal coordination complex K4[Fe(CN)6] is an efficient and environmentally benign catalyst for the synthesis of imidazolines and benzimidazoles from various aldehydes and 1,2-diamines in aqueous medium at room temperature. This protocol gives excellent yield of product with desired purity. Copyright

Synthesis, antimycobacterial activities and Docking studies of some novel diaryl imidazoles targeted at mycobacterium tuberculosis P-45014DM

A novel series of nine 2-(substituted phenyl)-1H-imidazol-1-yl-N- (substituted phenyl) alkanamides 3a-i were synthesized by reacting the corresponding w-chloroalkanamides 1 with 2-(substituted phenyl)-1H-imidazoles 2 in dimethylformamide. The compounds have been characterized on the basis of elemental analysis and spectral data. All the compounds were evaluated for their antimycobacterial activity. Among the synthesized compounds, N-(2,4-dinitrophenyl)-2-(2-(2-nitrophenyl)-1 H-imidazol-2-yl) propanamide 3e showed significant antimycobacterial activity when compared with the standard drug ethambutol. Docking studies with 14-a-demethylase (PDB ID IEA1) were also performed in order to investigate the binding pattern of these compounds.

Synthesis, antimicrobial and antimycobacterial evaluation of [2-(substituted phenyl)-imidazol-1-yl]-pyridin-3-yl-methanones

A series of [2-(substituted phenyl)-imidazol-1-yl]-pyridin-3-yl-methanones (111) were synthesized and screened for their antimicrobial and antimycobacterial activities. Further, a series of [2-(substituted phenyl)-benzimidazol-1-yl]-pyridin-3-yl-methanones (1220) reported in our earlier study was also screened for their antimycobacterial activity. The antimycobacterial activity results indicated that [2-(4-Nitro-phenyl)-imidazol- 1-yl]-pyridin-3-yl-methanone (8, minimum inhibitory concentration [MIC]=3.13 g) was equipotent as standard drug ciprofloxacin and [2-(4-Nitro-phenyl)- benzimidazol-1-yl]-pyridin-3-yl-methanone (16, MIC=1.56 g) was equipotent as standard drug ethambutol. The results of antimicrobial screening demonstrated that 2-[1-(Pyridine-3-carbonyl)-1H-imidazol-2-yl]-benzoic acid (compound 11, MIC=0.002 g) was two times more effective than standard drug ciprofloxacin (MIC=0.004 g) against tested bacterial strains and [2-(2,5-Dimethyl-phenyl)- imidazol-1-yl]-pyridin-3-yl-methanone (compound 3, MIC=0.005 g) was equipotent to the reference compound, fluconazole against tested fungal strains.